.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Key Issues Surrounding the Treatment of Prostate Cancer

EP. 1: Triggers to Initiate Androgen-Deprivation Therapy (ADT) in Prostate Cancer

December 1st 2016

EP. 2: Advanced Imaging Techniques for Prostate Cancer

December 1st 2016

EP. 3: Intermittent versus Continuous Androgen-Deprivation Therapy in Prostate Cancer

December 1st 2016

EP. 4: Multidisciplinary Approach and Role of PSA and Testosterone Monitoring in Prostate Cancer

December 1st 2016

EP. 5: Use of LHRH Agonists Versus Antagonists in Prostate Cancer

December 1st 2016

EP. 6: Decisions on Choosing LHRH Agonists for Treating Prostate Cancer

December 1st 2016

EP. 7: Challenges in Treating Nonmetastatic Castration-Resistant Prostate Cancer

December 1st 2016

EP. 8: Clinical Trials in Nonmetastatic Castration-Resistant Prostate Cancer

December 1st 2016

EP. 9: FDA-approved Indications for Treatment Versus Use in Current Clinical Trials

December 1st 2016

EP. 10: Radium-223 Alone and with Other Agents for Prostate Cancer

December 1st 2016

EP. 11: Immunotherapy and the Abscopal Effect in Treating Metastatic Prostate Cancer

December 1st 2016

EP. 12: Identifying Bone Progression in Metastatic Prostate Cancer and Treatment Options

December 1st 2016

EP. 13: PARP Inhibitors in BRCA1/2-mutated Patients in Prostate Cancer

December 1st 2016

EP. 14: Future of Genetic Testing and Treatment in Prostate Cancer

December 1st 2016